摘要
目的通过检测哮喘患者气道血管内皮生长因子（VEGF）和受体（VEGFR1）的表达，探讨VEGF和哮喘患者气道重塑的关系以及布地耐德／福莫特罗对哮喘患者气道重塑的调控作用。方法支气管组织来源于2006年4～11月四川大学华西医院经纤维支气管镜行组织活检。23例为中度哮喘患者，20例为对照组。哮喘患者给予规律吸入布地耐德／福莫特罗4．5／160μg，2次／日，持续6个月。VEGF和VEGFR1通过免疫组化进行检测。AB-PAS和Masson Trichrome染色用于评估气道重塑程度。结果两组之间年龄、性别差异无统计学意义。而两组之间FVC％预计值，FEV1％预计值，PC20，V75％预计值，V50％预计值和V25％预计值的差异具有统计学意义。哮喘组患者气道黏液腺增生、平滑肌增厚、上皮下纤维化以及新生血管增加。与对照组比较，VEGF和VEGFR1阳染细胞数目增多，表达增加。VEGF和VEGFR1表达增加与哮喘患者的气道重塑、气流阻塞和气道高反应性呈正相关。规律吸入布地耐德／福莫特罗6个月后，哮喘患者VEGF和VEGFR1表达减少，气道重塑减轻。结论伴随哮喘患者气道血管生成增多和气道重塑，VEGF和VEGFR1表达增加。规律吸入布地耐德／福莫特罗可以通过减少VEGF和VEG—FR。1表达而减轻哮喘患者气道重塑。阻断VEGF和VEGFR1可能是治疗哮喘的新策略。
Objective We examined the expression levels of VEGF and its receptor in bronchial tissues of patients with asthma to investigate the relationship between VEGF and airway remodeling and the efficiency of Budesonide Formoterol on the airway remodeling. Methods Bronchial tissues were obtained from fiberoptic bronehoscopy and bronchial biopsy in West China Hospital from April to November in 2006. Thirteen patients were diagnosed as patients with moderate asthma, and other 10 were the control subjects. The patients with asthma were treated with Budesonide-Formoterol for 6 months. The expression of VEGF and VEGFR1 in bronchial tissues were detected by immunohistoehemical stain. Periodic Acid Schiff （PAS） and alcian blue stain, and Masson Trichrome stain were performed to evaluate the degree of airway remodeling. Results The differences of age and gender between two groups were not significant. Otherwise, the differences of FVC % pred, FEV1 % pred, PC20, V75 % pred, V50 % pred and V25 % pred were significant between two groups. The patients with asthma had submucosal gland hyperplasia,increased smooth muscle mass, subepithelial fibrosis and neovascularization, compared to subjects in the control group. The asthma groups showed increased expressions of VEGF and VEGFR% ,more positively-stained cells of airway epithelial cells than the control group. The up-regulated expressions of VEGF and its receptor well correlated with the airway remodeling,air flow obstruction and airway hyperresponsiveness. After treatmented with Budesonide-Formoterol for 6 months, the expression of VEGF and VEGFR1 had been decreased,with decreased airway remodeling in patients with asthma. Conclusion The increased expression of VEGF and its receptor are accompanied by increased number and size of vessels in asthmatic airway,as well as airway remodeling. Budesonide-Formoterol can decrease the expression of vascular endothelial growth factor and receptor 1 with airway remodeling in asthma. The inhibition of VEGF and its receptor may be a good the
出处
《重庆医学》
CAS
CSCD
2008年第20期2295-2298,共4页
Chongqing medicine
基金
中国博士后基金资助项目(20070411154)
关键词
血管内皮生长因子
血管内皮生长因子受体1
气道重塑
哮喘
布地耐德/福莫特罗
vascular endothelial growth factor
vascular endothelial growth factor receptor 1
airway remodeling
asthma
budesonide-formoterol
